乾癬性關節炎市場：KOL 洞察

Psoriatic Arthritis - KOL Insight

出版日期: 2024年05月21日 | 出版商:

FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告檢視了全球乾癬性關節炎（PsA）市場，從經過驗證的安全性和有效性的抗 TNF 藥物的持續優勢，到Bimzelx作為利基療法的潛力，到 Skyrizi/Tremfya 在皮膚狀況管理方面的卓越功效，研究了當前和新興的治療方法，並對影響當今 PsA 管理臨床決策的策略偏好和實踐提供了寶貴的見解。

抗腫瘤壞死因子劑
- 主要見解摘要
白血球介素17抑制劑
- Cosentyx（secukinumab; Novartis）
- Taltz（ixekizumab，ixekizumab; Lilly）
- Bimzerx（bimekizumab; UCB）
Interleukin-12/23 和 interleukin-23 抑制劑
- Stelara (ustekinumab; Johnson & Johnson)
- Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
- Tremfya (guselkumab; Johnson & Johnson)
Janus 激酶（JAK）抑制劑
- Xeljanz (tofacitinib; Pfizer)
- Rinvoq (upadacitinib; AbbVie)
T細胞活化抑制劑
- Orencia（abatacept; Bristol Myers Squibb）
4型環核苷酸磷酸二酯酶抑制劑
- Otezla（apremilast; Amgen）

在研藥物

白血球介素17抑制劑
- Brodalumab（AstraZeneca/LEO Pharma）
- Izoquivep（Afibody/Aceririn）和 Sonelokimab（MoonLake Immunotherapeutics）
白血球介素23抑制劑
- Ilumya/Ilmetri（tildrakizumab、Almirall/Sun Pharmaceutical）
酪胺酸激酶 2（TYK2）抑制劑
- Sotiktu（deucravacitinib; Bristol Myers Squibb）
- TAK-279（Takeda）
Kv1.3鉀通道抑制劑
- si-544（選擇）

乾癬關節炎治療的未來趨勢與可能性

附錄

KOL報表

簡介目錄

Insights from leading KOLs on the evolving landscape of psoriatic arthritis (PsA) treatment. From the continued dominance of anti-TNFs due to their proven safety and efficacy to Bimzelx's potential as a niche treatment and Skyrizi/Tremfya's superior efficacy in managing skin symptoms, this report examines current and emerging therapies providing valuable insights into the strategic preferences and practices that are shaping clinical decisions in PsA management today.

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs (105)

Anti-tumour necrosis factor agents
- Key insights summary
Interleukin-17 inhibitors
- Cosentyx (secukinumab; Novartis)
- Taltz (ixekizumab; Lilly)
- Bimzelx (bimekizumab; UCB)
Interleukin-12/23 and interleukin-23 inhibitors
- Stelara (ustekinumab; Johnson & Johnson)
- Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
- Tremfya (guselkumab; Johnson & Johnson)
Janus kinase (JAK) inhibitors
- Xeljanz (tofacitinib; Pfizer)
- Rinvoq (upadacitinib; AbbVie)
T-cell activation inhibitors
- Orencia (abatacept; Bristol Myers Squibb)
Type 4 cyclic nucleotide phosphodiesterase inhibitors
- Otezla (apremilast; Amgen)

Pipeline drugs

Interleukin-17 inhibitors
- Brodalumab (AstraZeneca/LEO Pharma)
- Izokibep (Affibody/ACELYRIN) and sonelokimab (MoonLake Immunotherapeutics)
Interleukin-23 inhibitors
- Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
Tyrosine kinase 2 (TYK2) inhibitors
- Sotyktu (deucravacitinib; Bristol Myers Squibb)
- TAK-279 (Takeda)
Kv1.3 potassium channel inhibitor
- si-544 (selectION)